Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
63
mentions
- X 47
- News 11
- YouTube 2
- Blogs 2
- +1 more
